Transforming growth factor-β pathway activity in glioblastoma

Frei, K; Gramatzki, D; Tritschler, I; Schroeder, J J; Espinoza, L; Rushing, E J; Weller, M

Abstract: Transforming growth factor (TGF)-β is a central molecule maintaining the malignant phenotype of glioblastoma. Anti-TGF-β strategies are currently being explored in early clinical trials. Yet, there is little contemporary data on the differential expression of TGF-β isoforms at the mRNA and protein level or TGF-β/Smad pathway activity in glioblastomas in vivo. Here we studied 64 newly diagnosed and 16 recurrent glioblastomas for the expression of TGF-β1-3, platelet-derived growth factor (PDGF)-B, and plasminogen activator inhibitor (PAI)-1 mRNA by RT-PCR and for the levels of TGF-β1-3 protein, phosphorylated Smad2 (pSmad2), pSmad1/5/8 and PAI-1 by immunohistochemistry. Among the TGF-β isoforms, TGF-β1 mRNA was the most, whereas TGF-β3 mRNA was the least abundant. TGF-β1-3 mRNA expression was strongly correlated, as was the expression of TGF-β1-3 mRNA, and of the TGF-β1-3 target genes, PDGF-B and PAI-1. TGF-β2 and TGF-β3 protein levels correlated well, whereas the comparison of the other TGF-β isoforms did not. Positive correlation was also observed between TGF-β1 and pSmad1/5/8 and between pSmad2 and pSmad1/5/8. Survival analyses indicated that a group of patients with high expression levels of TGF-β2 mRNA or pSmad1/5/8 protein have inferior outcome. We thus provide potential biomarkers for patient stratification in clinical trials of anti-TGF-β therapies in glioblastoma.

DOI: 10.18632/oncotarget.3467
Neurodegeneration in the Elderly – when the blood type matters

An overview of the McLeod Syndrome with focus on hematological features

B.M Frey¹, C. Gassner¹, H.H. Jung²

¹) Blood Transfusion Service SRK, 8952 Schlieren-Zurich, Switzerland

²) Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Corresponding author: Beat M. Frey, Blood Transfusion Service SRK, Rütistrasse 19, 8952 Schlieren-Zurich, Switzerland

Tel: 0041 (0)58 272 52 52

Email: bm.frey@zhbsd.ch

www.zhbsd.ch
Summary

Multisystem deterioration occurs mainly in older individuals and may be related to physiological tissue degeneration. However, genetic predisposition may be unmasked by inappropriate functional and structural system deficiencies. McLeod Syndrome (MLS) is a rare, multisystem disease which is X-chromosomal inherited and belongs to the Neuroacanthocytosis Syndromes (NAS). The main clinical manifestations contain progressive neuro-psychiatric and cognitive deterioration, choreatic movement disorder, as well as myopathy, sensorymotor axonal neuropathy and cardiomyopathy. In addition, MLS patients have red blood cell abnormalities including immune-hematological, morphological and functional impairments of red blood cells. In large deletions, contiguous gene syndrome may arise, including Duchenne muscular dystrophia, cellular immunodeficiency or retinitis pigmentosa. Hematological abnormalities such as blood group abnormalities in Kell- and XK blood group system, formation of anti-public red blood cell alloantibodies, acanthocytosis and elevated creatinine phosphokinase may precede clinical disease manifestation for decades and provide tools for early diagnosis. Patients with unexplained neuro-muscular deterioration and/or neuro-psychological pathologies accompanied with hematological abnormalities should be investigated for MLS.
McLeod Syndrom (MLS) is part of the Neuroacanthocytosis Syndromes (NAS)

NAS are defined as progressive neurodegenerative diseases affecting mainly basal ganglia including nucleus caudatus and putamen in association with red blood cell acanthocytosis. Additional hematological abnormalities e.g. morphological, functional and serological aberrations of red blood cells (RBC) are part of disease defining clinical features.1-3. Four different diseases with overlapping clinical manifestations account for the NA syndromes: Choreoacanthocytosis (ChAc) and the McLeod syndrome (MLS) constitute the core NAS and are caused by mutations of the VPS13A gene on chromosome 9q21 and the XK gene on Xp21.1, respectively. The more rare diseases such as Huntington-like2 disease (HDL2) and the pantothenate kinase 2 disease (PKAN) complete the group of NAS. Affected genes and proteins, mechanism of inheritance and clinical as well as laboratory phenotypes are summarized in table 1.

Usually, the MLS is diagnosed in patients with progressive neuro-psychiatric deficiencies and having excluded other pathologies such as Huntington´s disease, Tourette’s syndrome and familial hemolytic anemia. The clinical picture reflects a neuro-hematological disorder4 where the subtle hematological findings may precede the neurological deficiencies for decades and remain unrecognized until neuro-psychiatric alterations prompt invasive assessment. The patients suffer on premature dementia, intellectual and cognitive impairment, depression, personality changes, social retraction and in some cases they may suffer of movement disorders such as choreatic movement disorder and dystonia as well as generalized epileptic seizures1,2,5-12. In all MLS patients examined up to date creatinine phosphokinase (CPK) is elevated, without signs of acute myocardial and muscular cell necrosis or renal insufficiency. The diagnostic key feature is the prototypic McLeod blood group phenotype comprising weakened or absent Kell blood group antigens and negativity for the Kx antigen on the red blood cell membrane. This blood group abnormality is
highly specific for MLS and separates the disease from other NAS. In many patients with MLS the blood group peculiarity goes along with acanthocytosis of variable degree and compensated hemolytic anemia. However, several individuals have been described with exclusive McLeod RBC phenotype without other hematological, neuro-psychiatric and neuro-muscular symptoms\textsuperscript{13,14}. Mostly, these cases are recognized when being blood group phenotyped for KEL antigens while serving as blood donors. Infact, the first case discovered with the prototypic RBC phenotype was the healthy blood donor Mr. McLeod, who engaged into blood donation as a dentist student and was diagnosed with “a new phenotype (McLeod) in the Kell blood group system”\textsuperscript{15} because of weakened expression of several Kell antigens as compared to his parents.

**Peculiarity of blood group antigens on McLeod erythrocytes**

The MLS is the only NAS with distinct blood group abnormality affecting the KEL (ISBT 06) as well as the XK (ISBT 019) blood group system. The Kell glycoprotein (CD238) is a type II single-pass transmembrane red blood cell protein containing 732 aminoacids and functions as an endopeptidase which cleaves big-endothelin3 into the active endothelin3, that acts as a potent vasoconstrictor\textsuperscript{16,17}. It expresses at least 35 recognized blood group antigens, including 5 antithetical pairs exerting clinical relevance\textsuperscript{18}. From these, the K/k pair (Kell/Cellano) is the most important one\textsuperscript{19}. The single aminoacid exchange of methionine replacing threonine at position 193 (Met193Thr) eliminates a N-glycosylation site of the Kell protein constituting the K (KEL1) and k (KEL2) epitopes, respectively. Alloantibodies against K and k may cause severe hemolytic transfusion reactions as well as live-threatening morbus hemolyticus neonatorum\textsuperscript{19,20}. 
The XK protein, encoded by the \( XK \) gene at Xp21.1 is a 444 aminoacid multipass red blood cell membrane peptide, forming a heterodimer with the Kell glycoprotein and expresses the single blood group antigen Kx\(^{21,22} \). The antigen Kx is located at the fifth extracellular loop of the XK peptide in close proximity to the disulfide bond \( \text{XKCys}^{347} - \text{KellCys}^{372} \), covalently linking and stabilizing the Kell-XK heterodimer\(^{22} \). In most ethnicities, the frequency of the Kx antigen is >99% and may therefore be considered as “the public Kx phenotype”\(^{19} \). Individuals with the McLeod phenotype, characteristically lack the Kx antigen, which is due to a complete absence or a drastically shortened XK protein and may rise anti-public red blood cell antibodies such as anti-Kx and anti-Km upon immunizing events, such as transfusion. These alloantibodies will react with most of the homologous blood donations and may therefore generate substantial problems in the supplementation with correctly matched, e.g. Kx negative blood\(^{4,13,23} \). In Kx negative individuals, the observed weakened agglutination of Kell antigens serves as surrogate for the McLeod phenotype and needs to be distinguished from a modified Kell antigen expression in Kmod and Knull phenotypes. These, equally rare variants of \( KEL \) alleles lead to modified Kell protein expression\(^{24,25} \) without molecular, phenotypic and clinical signs of MLS. The red blood cells of Kmod and Knull phenotypes express the Kx antigen\(^{24,26,27} \) and will therefore not develop anti-public antibodies in the Kx blood group system.

Genetic defects at Xp21.1 lead to the absence or truncation of the XK protein causing both, the reduced or complete absence of the Kell antigen in the erythrocyte membrane, as well as the absence of the Kx blood group antigen (Kx-)\(^{5} \). At least 29 different mutations at Xp21.1 are recognized as molecular mechanism for the Kx-phenotype\(^{5,18} \). These are missense and stop mutations anywhere in the three exons of the coding sequence as well as splice site and insertion/deletion mutations leading to erroneous translation and transcription of the gene, respectively\(^{5} \). In cases of large
deletional defects, neighbour genes of XK may also be affected and give rise to the “contiguous gene syndrome”\(^2\), of which the clinical phenotype is dominated by the co-affected gene(s)\(^2\). Most important are deletions affecting DMD, a gene located telomeric to XK, leading to Duchenne muscular dystrophy\(^2\) or deletions affecting the centromeric CYBB gene, leading to X-linked granulomatous disease (X-CGD)\(^3\). Figure 1 gives an overview on some of the molecular defects at Xp21.1 and their consequences for the XK protein.

**Distinct morphology of McLeod erythrocytes**

Patients suffering on MLS or ChAc usually present with various degree of acanthocytosis in circulating blood, which may be visualized by light microscopy of a blood smear. The abnormally shaped RBCs (acanthocytes) are characterized by few irregular membrane protrusions\(^3\). They are different from echinocytes which show many, more regular and shorter membrane bulges. However, although the morphological variants are distinct, these RBC abnormalities are interchangeable and in most cases acanthocytes are accompanied by echinocytes\(^3\). Since the lipid composition of altered RBC is normal, the acanthocytic shape change results from impaired interaction of the membrane multiprotein complexes (MMPC) with the cytoskeleton of red blood cell\(^3\). The major RBC anion exchanger protein, band 3 (B3), one of the most abundant membrane protein, is organized either as a tetrameric B3-ankyrin complex, a dimeric B3-protein 4.1R complex (also called “junctional complex”) and as a free B3 protein\(^3\). The B3 multimeric entities are attached to various other transmembrane proteins such as glycophorin A and C, Rh protein/Rh associated glycoprotein (RhAG), Kell, XK and Duffy proteins as well as CD47 and Landstein-Wiener (LW) glycoproteins and thereby constitute the MMPC. The MMPC interact with the RBC cytoskeleton by recruiting linker proteins such as protein 4.2/ankyrin (ankyrin
complex) and protein 4.1R/adducin (4.1R complex)\textsuperscript{36-38}. The MMPC-cytoskeleton network controls the RBC discocytic shape and determines RBC deformability, rheological, adhesive and functional properties\textsuperscript{37,39,40}. Deficiencies in one or several proteins of MMPC impairing the MMPC-cytoskeleton interaction were found to cause inherited RBC membranopathies such as hereditary eliptocytosis, ovalocytosis, stomatocytosis and spherocytosis\textsuperscript{37,41-49}. Moreover, the cytoplasmic part of B3 as well as of other attached membrane proteins control a variety of metabolic pathways in RBC by binding to aldolases, kinases, oxidases and phosphatases\textsuperscript{50-58}.

However, not only deficiencies or dysfunction of RBC membrane proteins may lead to acanthocytosis. Also, hereditary disorders of lipid metabolism such as apolipoprotein A and vitamin E deficiency\textsuperscript{59,60} as well as a number of acquired conditions such as acute and chronic anemia, hepatitis, alcoholic liver cirrhosis, hypopituitarism, hypothyreoidism, malabsorption syndromes and malnutrition may be associated with acanthocytic shape change of RBC\textsuperscript{61}.

Acanthocytic RBCs are a typical finding in NAS especially in patients with MLS and ChAc. However, the finding is neither specific nor sensitive enough for clinical diagnosis\textsuperscript{13,14}. Moreover, the in vitro diagnosis of acanthocytes is technically demanding and prone of false positive testing\textsuperscript{62}. Therefore, Storch et al. suggested a modified technique to assess peripheral blood smears for acanthocytes. According to Storch et al., quantification of acanthocytes needs to be done using wet smear of diluted blood sample and by applying dark filed microscopy\textsuperscript{62}. Due to technical demanding procedure and the low disease specificity of acanthocytes, this test has lost its diagnostic power. Nevertheless, functional impairment of transmembrane ion transport\textsuperscript{58,63-65}, impaired formation of endovesicles by acanthocytes in NAS\textsuperscript{56}, and the findings by DeFranceschi et al. who described 14 kinases constituting a mutual phospho-tyrosine sub-network in acanthocytes of NAS\textsuperscript{51} suggest common pathways
for acanthocyte formation and neurodegeneration in NAS. Therefore, acanthocytes of MLS may provide an easy accessible substrate to be investigated for pathomechanism of disease and may paste new avenues of treatment options for patients suffering on NAS.

**MLS is a multisystem disorder**

Although the genetic alteration in MLS was precisely located at Xp21.1\(^67\) the genotype-phenotype correlation is weak and most mutation carriers are discovered while being assessed for a wide spectrum of subtle to severe central nervous system or neuromuscular affection occurring together with pathological changes of red blood cells (acanthocytosis, coombs-negative, hemolytic anemia)\(^1\)\(^3\),\(^68\). The molecular characterization of underlying genetic defects in NAS allow unambiguous distinction between the four different entities of NAS (Table 1). Molecular defect identification has therefore become the key tool for diagnosis\(^1\),\(^,69\). In MLS, the disorder is caused by the affection of the XK protein, which is expressed ubiquitously in body tissues\(^70\) and most likely functions as a membrane transporter\(^71\),\(^72\) with so far not precisely defined substrate. In the RBC membrane the XK protein is co-expressed with the Kell protein and forms a heterodimer\(^22\),\(^27\),\(^70\),\(^73\). In contrast, non-hematopoietic cells express the XK protein independently of the Kell protein which may not even be present\(^70\). Therefore, XK may act as a universal gatekeeper by direct or indirect control of substrate exchange between different subcellular compartments\(^70\),\(^72\). Several groups have shown, that in the absence of XK or other RBC membrane proteins, the RBC shape and transmembrane ion transport may be severely altered. Active ion transport channels including the Ca\(^{2+}\) dependent K\(^+\) transport (Gardos channel) as well as the transporters of Mg\(^2+\), Cl\(^-\), SO\(_4\)- and other ions are negatively affected\(^58\),\(^63\),\(^65\),\(^66\),\(^74\). Especially, the proper function of Gardos channel is pivotal for the integrity and
function of RBCs\textsuperscript{75-78}. Gardos channels are ubiquitously expressed in body tissue\textsuperscript{79} and their functionality may depend on intact XK protein. In line with this assumption, disruption of XK may therefore lead to multisystem deficiencies by impairment of Gardos functionality which could explain the chef affected cardiac and neuronal tissues in MLS\textsuperscript{79-83} (see Table 1).

**Molecular MLS Assessment**

As detailed earlier, the NAS are monoallelic deficiency syndromes, perfectly suited for molecular defect analysis. The genetic defects of MLS always involve \textit{XK}, the gene encoding the XK protein and its Kx antigen, which is located at Xp21.1. The genetic lesions may be point mutations leading to amino acid exchanges and stop codons, splice site mutations and small insertional and deletional aberrations (indels), as well as large X-chromosomal deletions involving up to approximatively 5 Mio bp, as reported as of yet. A listing of all currently known XK-null alleles, e.g. \textit{XK*N01} to \textit{XK*N29}, may be retrieved from the homepage of the ISBT terminology committee\textsuperscript{18}. The mode of inheritance of MLS is X-chromosomal recessive, implying carrier status with no, or abrogated clinical disease manifestation in mothers, sisters and daughters of affected males. To exclude a disease caused by a molecular defect at Xp21.1, we designed a systematic approach to investigate the regions, telomeric and centromeric to \textit{XK} for the unique identification of contiguous gene defects. In brief, the X-chromosome is investigated in between \textit{OTC} (Ornithine Carbamoyltransferase at \textit{Xp11.4}, OMIM*300461) and \textit{DMD} (Duchenne Muscular Dystrophy, Dystrophin 1 at \textit{Xp21.2}, OMIM*300377), by 36 equally distanced positional PCRs also co-amplifying sequences of the Human Growth Hormone 1 (\textit{GH1} at \textit{17q23.3}, OMIM*139250), which serve as positive amplification controls. The X-chromosomal distance investigated by this approach covers more than 8.8 Mio basepairs (bp) in total and includes \textit{XK}, 0.7
Mio bps from its centromeric end (McLeod Syndrome associated XK at Xp21.1, OMIM*314850), as well as CYBB (Cytochrome b(-245) subunit associated with X-CGD at Xp11.4, OMIM*300481) and RPGR (Retinitis Pigmentosa GTPase Regulator at Xp11.4, OMIM*312610). In case of large X-chromosomal deletions, certain positional PCRs will fail to amplify. The indicated gap is then narrowed down by additional positional PCRs until the breakpoint of the deletion may be bridged by one single PCR. Consequently, this case specific PCR product is then sequenced and allows for the exact definition of the breakpoint position, and may itself already be used as highly accurate diagnostic tool for the detection of a carrier status in mothers, sisters and daughters of affected males. In case, no large X-chromosomal deletion is observed, all three XK exons, also including some sequences of the promoter and at least 50 bp of each flanking intron will be sequenced to reveal point mutations within the gene, potentially causative of an XK inactivating effect. The effect of such point mutations may be clearly evident, e.g. when nonsense mutations lead to the creation of stop codons in the predicted XK peptide, or be less informative and of questionable meaning, e.g. when exchanged amino acids share in between no, and up to similar physiochemical properties, then called “radical” and “conservative missense mutations”, respectively. Using this approach we were able to describe five intragenic XK mutants, with only one of them already known and listed as XK*N.20 by the ISBT terminology committee, the others, with as yet undescribed nonsense (n=1), frame shift (n=1) and radical missense mutation (n=1) and two large X-chromosomal deletions, respectively. All carriers had different MLS phenotypes including neuropsychiatric disorder associated with hereditary sudden death syndrome, severe choreatic movement disorder and X-linked CGD, in one case (manuscript in preparation).
Clinically guided MLS diagnosis

Most of the MLS mutations described so far were discovered in patients being investigated for neuro-psychiatric or choreatic movement disorders or in cases with immune deficiency syndromes. Normally, the patients suffer of unspecific neuro-psychiatric symptoms for years without having assigned clear diagnosis. Sometimes, MLS is diagnosed in asymptomatic mutation carriers, most often when routinely phenotyped for KEL antigens while serving as blood donors. These blood donors may develop clinical MLS later on and available data indicate a high penetrance of the disorder with a possible onset in the sixth and seventh decade. However, in patients with unexplained neuro-psychiatric problems or choreatic movement disorders with onset in the third or fourth decade it might be important to exclude MLS as the underlying disease causing condition. The findings may have important implications for the usually male patient as well as for his family members. Although the disease progression cannot be stopped, early supportive measures such as seizure protection, psychiatric treatment as well as prevention of mutilating involuntary movements may provide desired palliation of disease associated disabilities. Importantly, early recognition of orofacial dystonia may be pivotal to prevent feeding impairment and secondary wasting disease. Also, the recognition of private blood type (Kx-) is crucial when it comes to transfusion support. By timely searching for Kx- blood donors from international donor registries or alternatively, by use of cryopreserved autologous blood units the formation of anti-public antibodies can be prevented. Finally, cardiac complications such as fatal arrhythmia may be prevented by implantation of a cardiac pacemaker.

For genetic counselling of MLS patient’s family members, it is important to identify the exact genetic defect which can then be followed for segregation in the relatives of the patient. Finally, in X-linked CGD patients, the exclusion of mutations at Xp21.1 is
pivotal in planning and exertion of CGD treatment which often includes stem cell transplantation and transfusion support\textsuperscript{87,88}.

We established an algorithm to comprehensively assess patient’s samples for suspected McLeod mutations (Figure 2). Firstly, the patient’s RBCs are examined for expression of the Kx antigen as well as several antithetical Kell antigens (e.g. K, k, Kp\textsuperscript{b}) by conventional serology techniques. It is important to emphasize that IgG coating of patient’s RBCs needs to be excluded by negative direct antiglobuline test in order to validate serological antigen determination. Also, genetic investigation for inherited Kell antigens by commercial genotyping kits helps to confirm serological findings. In case the Kx antigen is absent and the inherited Kell antigens show weakened or missing expression, the McLeod red cell phenotype is proven. In such cases, the blood smear is assessed for the presence of acanthocytes and the extracted genomic DNA will be searched for disease causing mutations (see above). Identified mutations will then be used to design a molecular protocol to follow the segregation the of disease specific mutation in consanguineous family members. In order to complete an individual McLeod assessment, we further recommend to perform an expression study of the KEL protein by flowcytometry as described earlier\textsuperscript{13}. Flowcytometric investigation of KEL protein expression by using commercially available anti-Kell antibodies (e.g. BRIC18, BRIC68, BRIC203, provided by IBGRL, Bristol/UK) allows for a quantification of the circulating McLeod RBCs admixed to normal RBCs. Double RBC populations with normal and depressed KEL protein expression is a typical finding in female McLeod carriers\textsuperscript{4,7}. All individuals with confirmed McLeod RBC phenotype need to be assessed for the presence of red blood cell alloantibodies, since anti-public alloantibodies may have substantial consequences for transfusion support of MLS patients.
**Conclusion**

MLS is a rare multisystem disease which affects mainly male adults. Neuro-psychiatric, neuromuscular, cardial and hematologic affection dominate the clinical picture and may vary substantially in individual patients. Early diagnosis in patients with suggestive clinical symptoms is crucial for guiding the patient’s management in order to prevent cardial and hematologic sequelae and to palliate clinical and social consequences of disease. Diagnostic cornerstones are red blood cell phenotyping in the XK- and KEL system, appropriate molecular analysis of underlying genetic defect and quantification of circulating acanthocytes. The molecular mutation analysis also provides insights into multi gene defects (contiguous gene syndrome) which is most important in cases with juvenile X-linked granulomatous disease, retinitis pigmentosa and Duchenne muscular dystrophy.
Legends

**Table 1:**

*Genetic and somatic deficiencies in NA syndromes. Various genetic defects with distinct inheritance and overlapping clinical manifestation constitute the NA syndromes. Adapted from Jung et al*

*ChAc: Choreoacanthocytosis, MLS: McLeod Syndrome, HDL2: Huntington-like2 Syndrome, PKAN: Pantothenatekinase 2 Disease*
Figure 1:

The XK gene with its three exons and the corresponding red blood cell multipass membrane protein XK are shown. All three exons may be affected by stop and missense mutations leading to shortened or missing protein at the red cell surface. Also splice site mutation as well as partial and complete gene deletion mutations may cause absence of XK protein. Whole XK gene deletions extending to telomeric and centromeric coding regions may lead to the contiguous gene syndrome.

X: Marks premature termination of XK protein assembly due to stop codon
Figure 2:

Figure 2 delineates the systematic analysis of patient samples suspected for the presence of a McLeod mutation. The assessment always starts with the serological evaluation for KEL and Kx antigen expression, which are expected to be either negative or weakened. The antigen expression pattern needs to be validated by negative direct antiglobuline test. In case of positive DAT, the antigens might be determined false positive. Kx antigen expression pattern will then guide further evaluation performed. If Kx is negative, an assumed molecular defect directly encoded by the XK gene itself, or alternatively a large deletion affecting the expanded XK locus at Xp21.1 is checked for. Respective X-chromosomal mutations may then establish the diagnosis of McLeod syndrome and also explain the secondary weakened Kell antigen expression. If Kx reacts positive, the MLS is excluded and other reasons for weakened KEL expression might be checked for (K_{mod}, K_{Null}, Kp^{n+}). In MLS, further diagnostic steps may be taken, e.g. detailed FACS analysis of weakened Kell antigen expression, or a microscopic investigation for the presence of acanthocytes.

DAT: Direct Antiglobuline Test

FACS: Fluorescence Activated Cell Sorting
References


72. Subcellular locations from UniProtKB/Swiss-Prot, 2014.
Serological Assessment
Kell Antigens (e.g. K, k, Kp^b)
XK Antigen (Kx)
Direct Antiglobulin Test (DAT)

Molecular Assessment of Xp21.1

Molecular Assessment of Xp21.1

Kx?

KEL protein by FACS

Blood Smear (Acanthocytes?)

Normal KEL Phenotype McLeod excluded

Assessment for Kmod, Knull, Kp^a(*)

(*) Kp^a may explain weak expression of KEL antigens
<table>
<thead>
<tr>
<th>Phenotype</th>
<th>ChAc</th>
<th>MLS</th>
<th>HDL2</th>
<th>PKAN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gene/Chromosome</strong></td>
<td>VPS13A/9q21</td>
<td>XK/Xp21.1</td>
<td>JPH3/16q24.3</td>
<td>PANK2/20p13</td>
</tr>
<tr>
<td><strong>Protein</strong></td>
<td>Chorein</td>
<td>XK protein</td>
<td>Junctophilin-3</td>
<td>Pantothenate kinase 2</td>
</tr>
<tr>
<td><strong>Inheritance</strong></td>
<td>autosomal/recessive</td>
<td>X-linked/recessive</td>
<td>autosomal/dominant</td>
<td>autosomal/recessive</td>
</tr>
<tr>
<td><strong>Hemolytic anemia</strong></td>
<td>none</td>
<td>yes (not always)</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td><strong>Acanthocytes</strong></td>
<td>+++</td>
<td>++</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td><strong>Serum CK</strong></td>
<td>increased</td>
<td>increased</td>
<td>normal</td>
<td>normal</td>
</tr>
<tr>
<td><strong>Neuroimaging abnormalities</strong></td>
<td>striatal</td>
<td>striatal</td>
<td>striatal/cortical</td>
<td>striatal</td>
</tr>
<tr>
<td><strong>Age of onset</strong></td>
<td>20 - 30</td>
<td>25 - 60</td>
<td>20 - 40</td>
<td>&lt; 16</td>
</tr>
<tr>
<td><strong>Chorea</strong></td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td><strong>Other movement Disorders</strong></td>
<td>dystonia</td>
<td>vocalization</td>
<td>dystonia, parkinsonism</td>
<td>dystonia, parkinsonism, spasticity</td>
</tr>
<tr>
<td><strong>Seizures</strong></td>
<td>yes</td>
<td>yes</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td><strong>Neuromuscular defects</strong></td>
<td>areflexia</td>
<td>areflexia</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td><strong>Cardiac affection</strong></td>
<td>none</td>
<td>arrhythmias</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cardiomyopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>sudden cardiac death</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>